報價延遲最少15分鐘:2025/01/12 03:15 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.72 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-9.37/-4.94
|
|
企業價值
3.99B
|
| 資產負債 |
|
每股賬面淨值
3.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 03:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |